跳至主要内容
临床试验/JPRN-UMIN000008726
JPRN-UMIN000008726尚未招募未知

A pilot study to investigarte protective effects of a hydrogel dressing product from excerbation of atopic dermatitis. - A pilot study to investigarte protective effects of a hydrogel dressing product from excerbation of atopic dermatitis.

Kyusyu University Hospital0 个研究点目标入组 30 人开始时间: 2012年8月20日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients with oral steroids or oral cyclosporine Patients with a history of allergy for Ridomekkusu lotion, ointment, lotion Hirudoido ® or hydrogels Patients suspected of being pregnant or pregnant women Patients deemed inappropriate by the attending physician

研究者

发起方
Kyusyu University Hospital

相似试验

已完成
不适用
Combination therapy of Visudyne, Minocycline, Dexamethasone and Ranibizumab (VIMDER) for the treatment of subfoveal choroidal neovascularisation (CNV)Age-related macular degeneration
ISRCTN34410935King's College Hospital NHS Foundation Trust (UK)20
已完成
不适用
A pilot study to examine the safety and efficacy of posterior juxta-scleral (80 mg) triamcinolone acetonide, administration, in addition to Visudyne (verteporfin) photodynamic therapy for predominantly classic choroidal neovascularisation secondary to age-related macular degeneration: an open-label, randomised, active controlled trial
ISRCTN33957677King's College Hospital (UK)80
已完成
2 期
A pilot study to explore the efficacy and safety of jam oral immunotherapy with hypoallergenized cow's milk for children with cow's milk allergyfood allergy (cow&#39s milk)
JPRN-UMIN000018372ational Center for Child Health and Development10
招募中
2 期
Pilot cml autograft/glivec (STI571)/Intron A trialAdvanced phase chronic myeloid leukaemiaPh-positive acute lymphoblastic leukemiaCancer - Leukaemia - Acute leukaemia
ACTRN12605000071628Australasian Leukaemia and Lymphoma Group48
进行中(未招募)
不适用
A pilot study to examine the efficacy and safety of escitalopram in doses up to 50 mg for the treatment of patients with Major Depressive Disorder (MDD). - Resistant Depression StudyMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive Disorder
EUCTR2008-003359-58-GBCPS Research60